Respir Case Rep. 2021; 10(2): 78-82 | DOI: 10.5505/respircase.2021.60565

COVID-19 Pneumonia in two Patients with Ankylosing Spondylitis Using Anti-TNF Agents

Ýdris Kurt¹, Ebru Çakýr Edis², Habibe Tülin Elmaslar Mert^3
1Department of Internal Medicine, Trakya University Medical Faculty, Edirne, Turkey
²Department of Pulmonary Medicine, Trakya University Medical Faculty, Edirne, Turkey
³Department of Clinical Microbiology and Infection, Trakya University Medical Faculty, Edirne, Turkey

The new type of coronavirus (SARS-CoV2) reported to have originated in China in December 2019 has spread rapidly all over the world and has become a global problem. COVID-19 is more common and more severe in people with such comorbidities as cardiovascular disease, hypertension and diabetes. There is a lack of consensus on whether rheumatological diseases and drugs used in their treatment increase the risk of developing COVID-19. There is also lack of data in literature regarding the development of COVID-19, especially in patients with Ankylosing Spondylitis. This case presentation relates to two patients with Ankylosing Spondylitis using anti-TNF agents who were affected by COVID-19. The younger of the two, who had no comorbidities, healed quickly with antiviral and supportive therapy, while the older patient, who had cardiovascular and chronic kidney comorbidities, experienced an aggressive disease course and did not survive. The course of COVID-19 infection and mortality is strongly connected with underlying comorbidities. Our focus here is on rheumatological diseases, their immunosuppressive treatments and their impact on the course of the novel type Coronavirus infection, based on two cases of Ankylosing Spondylitis, in light of literature.

Keywords: Ankylosing Spondylitis, anti-TNF agents, COVID-19.

---

Anti-TNF Ajan Kullanan Ankilozan Spondilitli Ýki Hastada COVID-19 Pnömonisi

Ýdris Kurt¹, Ebru Çakýr Edis², Habibe Tülin Elmaslar Mert^3
1Trakya Üniversitesi Týp Fakültesi, Ýç Hastalýklarý Ana-bilim Dalý, Edirne
²Trakya Üniversitesi Týp Fakültesi, Göðüs Hastalýklarý Anabilim Dalý, Edirne
³Trakya Üniversitesi Týp Fakültesi, Klinik Mikrobiyoloji ve Enfeksiyon Hastalýklarý Anabilim Dalý, Edirne

Çin’de, Aralýk 2019’da görülmeye baþlanan yeni tip koronavirus (SARS-CoV2) hýzla tüm dünyaya yayýlmýþ ve küresel bir sorun haline gelmiþtir. Kardiyovasküler hastalýk, hipertansiyon, diyabet gibi komorbiditesi olan kiþilerde COVID-19 daha sýk rastlanmakta ve daha aðýr seyretmektedir. Romatolojik hastalýklarýn ve bunlarýn tedavisinde kullanýlan ilaçlarýn COVID-19 geliþme riskini arttýrýp arttýrmadýðý tartýþmalýdýr. Literatürde özellikle Ankilozan Spondilitli hastalarda COVID-19 geliþimi ile ilgili veri eksikliði mevcuttur. Biz bu olgu sunumunda Anti-TNF kullanýrken, COVID-19 enfeksiyonu geçiren, iki Ankilozan Spondilit’liyi sunmayý amaçladýk. Komorbiditesi olmayan genç hastamýz, antiviral ve destek tedavisi ile hýzlý þekilde iyileþti. Kronik kardiyovasküler ve böbrek hastalýðý olan yaþlý hastamýzýn seyri daha aðýr oldu ve hayat kaybý ile sonuçlandý. COVID-19 enfeksiyonun seyri ve mortalitesi, altta yatan komorbid hastalýklar ile yakýn iliþkilidir. Ankilozan Spondilitli iki olgu örneði üzerinden romatolojik hastalýklar ve kullanýlan immünsupresif tedavilerin yeni tip koronavirüs enfeksiyonu seyrine etkisini, literatür eþliðinde, tartýþmayý amaçladýk.

Anahtar Kelimeler: Ankilozan Spondilit, anti-TNF ajanlar, COVID-19.

---

Image Slices of the Case

#1

#2

---

CITE